DDInter192 DDInter1676
A long-acting, non selective, calcium channel blocker with significant anti-anginal activity. The drug produces significant coronary vasodilation and modest peripheral effects. It has antihypertensive and selective anti-arrhythmia activities and acts as a calmodulin antagonist. It is no longer marketed in the United States, as it has been implicated in causing ventricular arrhythmias (ie. Torsade de pointes).
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Bepridil {u} (Compound) resembles {v} (Compound) Diphenidol
Bepridil {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Diphenhydramine
Bepridil {u} (Compound) resembles {v} (Compound) Fentanyl
Bepridil {u} (Compound) treats {v} (Disease) hypertension
Bepridil {u} (Compound) binds {v} (Gene) CACNA1D
Bepridil {u} (Compound) causes {v} (Side Effect) Insomnia
Bepridil {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Bepridil {u} may cause a minor interaction that can limit clinical effects when taken with {v} Naloxegol
Bepridil {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Calcium glubionate anhydrous
Bepridil {u} may lead to a major life threatening interaction when taken with {v} Eliglustat
Bepridil (Compound) resembles Diphenidol (Compound)
Bepridil may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine
Bepridil (Compound) resembles Fentanyl (Compound)
Bepridil (Compound) treats hypertension (Disease)
Bepridil (Compound) binds CACNA1D (Gene)
Bepridil (Compound) causes Insomnia (Side Effect)
Bepridil may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Bepridil may cause a minor interaction that can limit clinical effects when taken with Naloxegol
Bepridil may cause a moderate interaction that could exacerbate diseases when taken with Calcium glubionate anhydrous
Bepridil may lead to a major life threatening interaction when taken with Eliglustat